Compugen Ltd. CGEN

NAS: CGEN | ISIN: IL0010852080   18/04/2024
1,880 USD (-1,05%)
(-1,05%)   18/04/2024

10 april 2024 · Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503 · Persbericht

3 april 2024 · Compugen to Participate in Two Upcoming Investor Conferences · Persbericht

11 maart 2024 · Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy · Persbericht

6 maart 2024 · Compugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024 · Persbericht

5 maart 2024 · Compugen Reports Fourth Quarter and Full Year 2023 Results · Persbericht

26 februari 2024 · Compugen to Present at the Leerink Partners Global Biopharma Conference 2024 · Persbericht

20 februari 2024 · Compugen to Release Fourth Quarter and Full Year 2023 Results on Tuesday, March 5, 2024 · Persbericht

15 februari 2024 · Compugen Announces Appointment of Michelle Mahler M.D. as Chief Medical Officer · Persbericht

8 januari 2024 · Compugen to Receive $10 Million Milestone Payment Following Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer · Persbericht

8 januari 2024 · Compugen Regains Compliance with Nasdaq Minimum Bid Price Requirement · Persbericht

19 december 2023 · Compugen will be Eligible to Receive $10 Million Milestone Payment upon Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer · Persbericht

19 december 2023 · Compugen to Host Conference Call to Discuss Exclusive License Agreement with Gilead for COM503, Novel Immuno-Oncology Pre-Clinical Program Harnessing IL-18 Biology · Persbericht

7 november 2023 · Compugen Reports Third Quarter 2023 Results · Persbericht

6 november 2023 · Compugen's COM701 (anti-PVRIG) Mediates Anti-Tumor Activity in Patients Typically Not Responding to Immunotherapy · Persbericht

3 november 2023 · Compugen Announces Receipt of Nasdaq Minimum Bid Price Notification · Persbericht

31 oktober 2023 · Compugen to Present New Data at SITC 2023 Suggesting Leading Edge of Anti-IL18 Binding Protein Antibody, COM503, in Treating Cancer · Persbericht

24 oktober 2023 · Compugen to Release Third Quarter 2023 Results on Tuesday, November 7, 2023 · Persbericht

3 oktober 2023 · Compugen to Present at Single Cell Genomics 2023 Meeting · Persbericht

2 oktober 2023 · Compugen Expands Intellectual Property with New Japanese Patent for the Triple Combination of any Anti-PVRIG, TIGIT and PD-1 Antibody for the Treatment of Cancer · Persbericht

27 september 2023 · Compugen to Present New Clinical and Pre-Clinical Data in Multiple Presentations at SITC 2023 · Persbericht

Mijn selecties